Clinical Trial Update: Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated vaccination with Poly-ICLC and peptide-pulsed dendritic cells for melanoma. The study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Hiltonol (Poly-ICLC)
• Peptide-pulsed dendritic cell vaccine (peptide-pulsed dendritic cell vaccine)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Melanoma | Phase 1 | Status: TERMINATED